Braile, Mariantonia (2021) Lipopolysaccharide-mediated neutrophil vegf-a release in modulated by cannabinoid reception activation. [Tesi di dottorato]

[thumbnail of Braile_Mariantonia_XXXIII.pdf]
Preview
Text
Braile_Mariantonia_XXXIII.pdf

Download (1MB) | Preview
Item Type: Tesi di dottorato
Resource language: English
Title: Lipopolysaccharide-mediated neutrophil vegf-a release in modulated by cannabinoid reception activation
Creators:
Creators
Email
Braile, Mariantonia
brailemariantonia@gmail.com
Date: 2021
Number of Pages: 39
Institution: Università degli Studi di Napoli Federico II
Department: Scienze Mediche Traslazionali
Dottorato: Medicina clinica e sperimentale
Ciclo di dottorato: 33
Coordinatore del Corso di dottorato:
nome
email
Beguinot, Francesco
UNSPECIFIED
Tutor:
nome
email
Marone, Gianni
UNSPECIFIED
Date: 2021
Number of Pages: 39
Keywords: Angiogenesis, cannabinoid system, sepsis
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/05 - Patologia clinica
Area 06 - Scienze mediche > MED/17 - Malattie infettive
Date Deposited: 19 Jul 2021 13:44
Last Modified: 07 Jun 2023 10:46
URI: http://www.fedoa.unina.it/id/eprint/14039

Collection description

Background: Neutrophils (PMNs) are innate immune cells with primary roles in inflammation and in host defense against infections. Both inflammatory and tumor angiogenesis are modulated by a sequential, coordinated production of angiogenic factors such as vascular endothelial growth factors (VEGFs), angiopoietins (ANGPTs), hepatocyte growth factor (HGF), and chemokines. These factors are produced by several immune cells, including PMNs. Activation of cannabinoid receptor type-1 (CB1) and -2 (CB2) has been suggested as a new strategy to modulate in vitro and in vivo angiogenesis. Objective: We sought to investigate whether activation of CB1 and CB2 by CB agonists modulate lipopolysaccharide (LPS)-mediated angiogenic activity of human PMNs. Methods: Highly purified PMNs were isolated from buffy coats of healthy donors. Cells were stimulated with CB1 and CB2 agonists/antagonists alone and/or in combination with LPS. Angiogenic factors in cell-free supernatants were measured by ELISA. The modulation of activation markers of PMNs by CB agonists was evaluated by flow cytometry. Angiogenesis in vitro was measured as tube formation by optical microscopy. Endothelial cell permeability was assessed by an in vitro vascular permeability assay. Results: LPS-activated PMNs released VEGF-A, CXCL8 and HGF. Preincubation of PMNs with low concentrations of CB1 and CB2 agonists inhibited VEGF-A release induced by LPS, but did not affect CXCL8 and HGF production. The effects of CB agonists on VEGF-A release induced by LPS were reversed by preincubation with CB antagonists. CB agonists modulated in vitro angiogenesis and endothelial permeability induced by supernatants of LPS-activated PMNs through the reduction of VEGF-A. Conclusions: Neutrophils play a central role in the control of bacterial infections and in the outcome of sepsis. The latter condition is associated with an increase in circulating levels of VEGF-A. We demonstrated that low concentrations of CB agonists inhibit VEGF-A release from LPS-activated PMNs. These results suggest that CB agonists might represent a novel therapeutic strategy in patients with sepsis.

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item